NewsRoom Articles - Page 2 of 256

FridayAug 02, 2024 9:00 am

Software Effective Solutions Corp. (SFWJ) Dedicated to Becoming Leader in Growing Cannabis Sector

A recent report projects that the cannabis market, which totaled an estimated $27.7 billion in 2022, will reach $82.3 billion by 2027 The forecast includes businesses and enterprises involved in the cultivation, processing, distribution and sale of cannabis and cannabis-related products MedCana is building technology, laboratories, growing facilities and scientific teams to provide premium pharmaceutical-grade cannabis extracts to the world With the worldwide cannabis market projected to see a compound annual growth rate (“CAGR”) of 24.3% in the next three years, Software Effective Solutions (d/b/a MedCana) (OTC: SFWJ) is committed to strengthening its foothold in the growing space. The company, which is committed…

WednesdayJul 31, 2024 9:45 am

Software Effective Solutions Corp. (SFWJ) Takes Critical Steps Toward Achieving Global Production and Processing Vision

MedCana has identified Colombia’s Antioquia Valley as a perfect location to begin its initial rollout of technology and production The company is working with five subsidiaries in the area, each of which has three licenses to produce, process and export cannabis Equally important to MedCana is working closely with the people of the Antioquia Valley and maintaining its commitments to its investors Cannabis legalization is not exclusive to North America. So far, more than 40 countries have legalized cannabis fully or partially for medical and/or adult use (https://cnw.fm/H7Jbq). With its focus on the global horizon, Software Effective Solutions (d/b/a MedCana)…

WednesdayJul 31, 2024 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Produces Notable Findings in Latest Weight Loss Study

Lexaria, a global innovator in drug delivery platforms, has released interim results from its WEIGHT-A24-1 animal study The study sought to explore the impact of its patented DehydraTECH technology on glucagon-like peptide-1 (“GLP-1”) drugs for the potential treatment of diabetes and weight loss, representing a major global market The first 28 days of dosing yielded positive results that Lexaria’s management described as “noteworthy” It also marked a significant milestone for the company and the first time it has used liraglutide in any of its GLP-1 studies Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery enhancement, just released interim…

WednesdayJul 24, 2024 9:00 am

InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-089, a Promising Treatment for Age-Related Macular Degeneration

Age-related macular degeneration is a disease significantly impacting the quality of life, making it difficult for individuals to perform everyday activities such as reading, driving, and recognizing faces InMed is currently developing a pipeline of drugs, like INM-089, to treat diseases with a high unmet medical need Delivers improved retinal pigment epithelium integrity, neuroprotection and photoreceptor improvement in in vivo preclinical disease model Age-related macular degeneration (“AMD”) is a prevalent eye condition that primarily affects older adults, leading to vision loss in the central part of the retina, known as the macula. This disease significantly impacts the quality of life, making it…

MondayJul 22, 2024 10:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) to Validate Earlier Semaglutide Studies with Successful GLP-1-H24-2 Study Dosing

Lexaria, a global innovator in drug delivery platforms, recently completed dosing of its human pilot study #2, GLP-1-H24-2 The study is to explore the tolerability, side effects, and blood levels of semaglutide, a glucagon-like peptide-1 (“GLP-1”) drug For Lexaria, the results from this study look to validate earlier studies that have demonstrated improvements in the delivery of semaglutide into the bloodstream Results from the GLP-1-H24-2 study are set to be announced in late August or early September Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced the dosing completion of its human pilot study #2, GLP-1-H24-2.…

WednesdayJul 17, 2024 10:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Issuance of Three New Patents, Growing Portfolio to 46 Granted Patents Worldwide

Considered intangible assets, patents offer a significant competitive advantage and value for companies Lexaria Bioscience views its growing patent portfolio as a solid foundation upon which to build future commercial partnerships The company recently announced the receipt of three new patents in the E.U., Canada, and the U.S. The issuance of the latest three patents grows Lexaria’s patent portfolio to 46 granted patents worldwide Lexaria’s multi-patented DehydraTECH(TM) “drug delivery platform technology” offers proven increased bioavailability, enhancing the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery, helping with speed of onset, and brain absorption of…

TuesdayJul 16, 2024 12:00 pm

420 Expo Consumer Cannabis Convention In NJ To Draw over 15,000 Enthusiasts

The third annual 420 Expo Cannabis Convention will be held Sept 13-15, 2024 at the New Jersey Convention & Exposition Center. The event is expected to bring over 15,000 cannabis enthusiasts together for three days of networking with cannabis industry traders from all over the country. In addition, the convention will feature seminars, panel discussions, food, music, after parties, and exciting giveaways. The event will also showcase a first-of-its-kind contest for licensed cultivators across the Garden State to compete for the 420 Expo Cannabis Cup until Sunday, July 28. In addition, B-Real, lead rapper of the multi-platinum hip-hop group Cypress Hill, will be gracing the event…

TuesdayJul 16, 2024 9:00 am

Software Effective Solutions Corp. (SFWJ) Strengthening Cannabis Foothold as CSA Status Set to Change

An overwhelming share of U.S. adults say marijuana should be legal for medical or recreational use, reports Pew Research Center The U.S. attorney general has submitted official notice to begin the process of moving marijuana from a Schedule 1 to Schedule 3 drug under the Controlled Substances Act MedCana is committed to building the technology, laboratories, growing facilities and scientific teams to provide premium pharmaceutical-grade cannabis extracts With a significant majority of Americans supporting cannabis use and the U.S. government on the verge of changing the status of the substance under the Controlled Substances Act (“CSA”), Software Effective Solutions (d/b/a MedCana) (OTC:…

MondayJul 15, 2024 10:30 am

Golden Triangle Ventures Inc. (GTVH), Lavish Entertainment Report on Progress of One-of-a-Kind Entertainment Destination

New project “set to transform luxury entertainment and hospitality,” according to company officials Critical development has included work on infrastructure and improvements Officials also focused on obtaining required permits, assembling key leadership and identifying ideal vendors A luxury destination featuring world-class entertainment, opulent accommodations and immersive experiences is rising in the Mojave Desert. The unique property, called Destino Ranch, is a bold, visionary project envisioned by Golden Triangle Ventures (OTC: GTVH) and its wholly owned subsidiary, Lavish Entertainment. Golden Triangle and Lavish Entertainment recently provided an update (https://cnw.fm/Rfq7n) on the one-of-a-kind project, which is “set to transform luxury entertainment and hospitality.” According to…

MondayJul 15, 2024 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Looking to Replicate Results from First GLP-1 Study Following CRO Contract Award for 12-Week Chronic Human Study

Lexaria, a global innovator in drug delivery platforms, recently hired a contract research organization (“CRO”) for its upcoming chronic human study, GLP-1-H24-4 This study will seek to evaluate various glucagon-like peptide-1 (“GLP-1”) formulations, processed with the company’s patented DehydraTECH(TM) technology The study will feature five arms, with each conducted using several investigational sites in Australia Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced the hiring of a contract research organization (“CRO”) that will be responsible for overseeing the execution of the company’s upcoming chronic human study, GLP-1-H24-4. This 12-week study will seek to evaluate various…

News and publishing service for CBD related companies

Contact us: 512.354.7000